Cost-Effectiveness of Tenecteplase Before Thrombectomy for Ischemic Stroke
Lan Gao, Marj Moodie, Peter J Mitchell, Leonid Churilov, Timothy J Kleinig, Nawaf Yassi, Bernard Yan, Mark W Parsons, Geoffrey A Donnan, Stephen M Davis, Bruce CV Campbell
Stroke | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
BACKGROUND AND PURPOSE: Tenecteplase improved functional outcomes and reduced the requirement for endovascular thrombectomy in ischemic stroke patients with large vessel occlusion in the EXTEND-IA TNK randomized trial. We assessed the cost-effectiveness of tenecteplase versus alteplase in this trial. METHODS: Post hoc within-trial economic analysis included costs of index emergency department and inpatient stroke hospitalization, rehabilitation/subacute care, and rehospitalization due to stroke within 90 days. Sources for cost included key study site complemented by published literature and government websites. Quality-adjusted life-years were estimated using utility scores derived from the ..View full abstract
Awarded by National Health and Medical Research Council of Australia
This study was supported by Medtronic (unrestricted grant), the National Health and Medical Research Council of Australia (1043242, 1035688, 1113352, and 1111972), the Royal Australasian College of Physicians, the Royal Melbourne Hospital Foundation, the National Heart Foundation of Australia, and the Stroke Foundation of Australia, and infrastructure funding from the state government of Victoria to the Florey Institute of Neuroscience and Mental Health.